C

큐리옥스바이오시스템즈

445680KOSDAQ

49.5 / 100

Reference Date: 2026-10-23

Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum15.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 26.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Curiox Biosystems sells automated equipment and consumables for cell analysis processes, leveraging its decade-long developed Curiox C-FREE™ technology to automate preprocessing steps, significantly improving data accuracy and reproducibility. This technology, based on microfluidics and surface science, is used by pharmaceutical companies and research institutions in the US, Europe, and China. The company has subsidiaries in the US, China, and Singapore to expand its global market presence.

Number of Employees

22people

Average Salary

70.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
19.28Industry Average 1.200.0Point

16.1x industry avg (risky)

ROE
-53.58Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
3.49Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼10.1% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼9.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -30.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 59,100Won52-week high 139,60052-week low 34,300
1-month return6.0Point

1m +26.15% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-10-02
  • Neutral[기재정정]사업보고서 (2025.12)2026-10-01
  • Neutral[기재정정]사업보고서 (2024.12)2026-10-01
  • Neutral[기재정정]사업보고서 (2023.12)2026-10-01